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Abstract
Background: In the global program for the elimination of lymphatic filariasis (LF) longitudinal assessment of the prevalence of
microfilaremia and antigenemia is recommended to monitor the effect of mass treatment on transmission. Additional monitoring
tools such as entomologic and antibody methods may be useful in identifying residual foci of infection. In this study, we
characterized serologic markers of infection and exposure spatially both before and after mass treatment, in an area of initial
low Wuchereria bancrofti infection prevalence.
Methods:  Consenting persons in the sentinel community were tested for circulating microfilaria and antigen (by
immunochromatographic test) before and after the 1st annual mass drug administration of diethylcarbamazine and albendazole.
A cohort of 161 persons provided serum specimens both years that were tested for antifilarial IgG (1 and 4) antibody. Every
house was mapped using a differential Global Positioning System; this information was linked to the serologic data. W. bancrofti
infection in the mosquito vector was assessed with year-round collection. Multiple linear regression was used to investigate the
influence of antigen-positive persons on the antifilarial antibody responses of antigen-negative neighbors.
Results: After mass treatment, decreases were observed in the sentinel site in the overall prevalence of antigen (10.4% to 6.3%)
and microfilaremia (0.9 to 0.4%). Of the persons in the cohort that provided serum specimens both years, 79% received
treatment. Antigen prevalence decreased from 15.0% to 8.7%. Among 126 persons who received treatment, antigen and
antifilarial IgG1 prevalence decreased significantly (p = 0.002 and 0.001, respectively). Among 34 persons who did not receive
treatment, antifilarial IgG1 prevalence increased significantly (p = 0.003). Average antifilarial IgG1 levels decreased in households
with high treatment coverage and increased in households that refused treatment. Each 10-meter increase in distance from the
residence of a person who was antigen-positive in 2000 was associated a 4.68 unit decrease in antifilarial IgG1 level in 2001,
controlling for other factors (p = 0.04).
Discussion: Antifilarial antibody assays can be used as a measure of filarial exposure. Our results suggest that micro-scale spatial
heterogeneity exists in LF exposure and infection. Treatment appeared to be associated with reduced exposure at the sub-
community level, suggesting the need to achieve high and homogeneous coverage. Public health messages should note the
benefits of having one's neighbors receive treatment with antifilarial drugs.
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Background
Lymphatic filariasis (LF) is endemic in more than 80
countries with approximately 120 million people infected
and over a billion people at risk [1]. Mass drug treatment
is one of the strategies that may allow the elimination of
this public health burden to become a reality. This effort
will require good monitoring tools for decision making,
for both the initiation (mapping) and cessation (demon-
stration of interruption of transmission) of LF elimination
programs.
Microfilaria (Mf) and antigen (Ag) testing have become
standard methods to measure the impact of LF elimina-
tion programs [2]. However, pockets of residual infection
may be difficult to recognize because the sensitivity of the
Mf and Ag tests are reduced as the intensity of infection
decreases and because practical sampling strategies have
not yet been developed that will identify small foci where
infection persists. Therefore, it is important to explore
other measures such as entomologic techniques and new
serologic assays for program monitoring and evaluation
[3,4].
Measuring prevalence of Wuchereria bancrofti infection in
mosquitoes has proven to be useful for monitoring LF
transmission during mass drug treatment programs [5,6].
Mosquito dissection is the most accepted method, but
when Mf prevalence and density are low, the utility of this
technique decreases. Polymerase chain reaction (PCR) is
more sensitive than dissection, and it has the practical
advantage of being useful for testing pools of mosquitoes
in areas of low transmission. However, PCR methods have
not yet been standardized for use in the LF elimination
program [7,8].
Antifilarial antibody (Ab) assays have been proposed as
potential monitoring tools. Antibody responses to W.
bancrofti develop prior to antigenemia, making them early
markers of exposure and infection [9-11]. In addition,
monitoring isotype-specific responses to filarial Ag may
provide a way to distinguish between exposure and active
infection. Using crude Brugia adult worm extracts as an
antigen source, studies comparing antibody responses in
high and low transmission settings have provided evi-
dence that antifilarial IgG1 response serves as a marker of
filarial exposure, while the antifilarial IgG4 response is
associated with the presence of circulating filarial Ag
[10,12-14]. Finally, previous studies, of both LF and
onchocerciasis, suggest that the lack of antifilarial anti-
body responses serve as a useful indicator of the absence
of transmission following implementation of control pro-
grams [15-17].
Mapping approaches have been used to determine the
geographic distribution of filarial disease and infection at
national and regional levels [18-23]. These large-scale spa-
tial assessments have been especially useful for identifying
implementation units for mass treatment programs, but
there is some indication that micro-scale spatial heteroge-
neity exists in LF infection [24-26]. Such heterogeneity
could be problematic for deciding where to initiate mass
treatment, since isolated pockets of transmission may be
missed during national-level mapping to identify areas
that require intervention [26]. Continued low-level trans-
mission in small areas also might be missed by the large-
scale sampling, currently recommended by WHO to deter-
mine whether transmission has been interrupted, result-
ing in a premature stoppage of mass treatment [2].
We conducted a study to characterize Mf, Ag, and Ab
responses both temporally (before and after mass treat-
ment) and spatially, in an area of initial low W. bancrofti
infection prevalence. The combined use of these tools
allowed us to develop a more complete picture of trans-
mission dynamics in our study site and helped us to doc-
ument the reduction of transmission following treatment.
We believe our results provide a further justification for
using antibody assays to monitor filarial exposure.
Materials and methods
Study location
The study was carried out in Mapou (Léogâne Com-
mune), Haiti, a W. bancrofti-endemic community with
approximately 1,000 residents located roughly 30 kilom-
eters west of Port au Prince (Figure 1). Mapou is situated
linearly along a road and adjacent to a seasonal river (Fig-
ure 2), approximately 8 kilometers from the coast.
Study populations
The study consists of two defined groups, the sentinel site
and the cohort. The sentinel site group is a convenience
sample of individuals who lived in Mapou during 2000
and 2001. The cohort data is made up of persons in the
sentinel site who have adequate stored sera from both
2000 and 2001. Both groups are described in greater
detail below.
Sentinel site data collection
Mapou is one of four sentinel sites chosen in Léogâne
Commune to monitor the impact of a Commune-wide LF
elimination demonstration project [2]. These sites were
surveyed before and after the first round of annual mass
treatment for W. bancrofti infection, in 2000 and 2001,
respectively; demographic data were also obtained during
these surveys. Before initiating monitoring activities, the
purpose of the testing was explained to the community in
Haitian Creole and individuals were asked to participate.
Verbal informed consent was obtained from all individu-
als. The protocol for this study was reviewed and
approved by the Institutional Review Board (IRB) of theFilaria Journal 2004, 3 http://www.filariajournal.com/content/3/1/3
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Centers for Disease Control and Prevention (Georgia,
USA), the IRB of the University of Notre Dame (Indiana,
USA), and the Ethical Committee of the Sainte Croix Hos-
pital (Léogâne, Haiti). Data were entered into an EpiInfo
6 database.
GPS Map
Every house in Mapou was mapped using a differential
Global Positioning System (DGPS) [27]. DGPS is used to
remove much of the error associated with ordinary Global
Positioning System (GPS) mapping methods. GPS error
was computed by comparing GPS readings at a known
location (Sainte Croix Hospital) for all available GPS sat-
ellites with the location's true coordinates. This error term
was used to calibrate the field mapping work, reducing
horizontal errors to an average of less than 3 meters. The
TSC1 Asset Surveyor with Pro XRS receiver was used to
enter the data and PathFinder software (v. 2.90) was used
for data transfer and differential correction (Trimble Nav-
igation Limited, Sunnyvale, CA, USA).
Examination of circulating antigen and microfilaria
Nocturnal "finger-prick" (capillary) blood was collected
(between 7 and 9 PM) in June-July 2000 (pre-treatment)
and July 2001 (post-treatment). Blood smears (20 µl-
thick films) were prepared in the field and later stained
Map of Haiti, indicating the commune of Léogâne and the community of Mapou Figure 1
Map of Haiti, indicating the commune of Léogâne and the community of Mapou.
Leogane Commune
Mapou
Port au
PrinceFilaria Journal 2004, 3 http://www.filariajournal.com/content/3/1/3
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with Giemsa and examined for the presence and number
of Mf as described elsewhere [9]. The same finger-prick
was used to collect 100 µl of blood for the immunochro-
matographic test (ICT, AMRAD, New South Wales, Aus-
tralia), which was used to determine Ag status (positive/
negative). Studies have shown that this test is more than
99% sensitive in persons with detectable bancroftian
microfilaremia [28].
Collection of sera
Additional finger-prick blood (200 µl) was collected at the
time of thick smear preparation and antigen testing for
use in antibody assays. After collection, blood was refrig-
erated overnight and the serum was separated by centrifu-
gation the following day. Sera were stored at -20°C.
GPS generated map of Mapou, showing houses, schools, mosquito trap locations, and other landmarks as indicated Figure 2
GPS generated map of Mapou, showing houses, schools, mosquito trap locations, and other landmarks as indicated.
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Entomology
W. bancrofti infection in the mosquito vector was assessed
with year-round mosquito collection in Mapou. Culex
quinquefasciatus is the primary vector of LF in Haiti [29-
31]. Gravid traps were used to collect female C. quinque-
fasciatus mosquitoes, seeking to oviposit. Such mosqui-
toes have blood fed at least once. Mosquitoes were
trapped for four consecutive nights fortnightly at five trap-
ping locations (Figure 2). Approximately half of the mos-
quitoes were dissected individually to determine numbers
and stages of W. bancrofti larvae present [6]. From this, we
estimated the prevalence of infected and infective mosqui-
toes in Mapou. An infected mosquito was defined as a
female C. quinquefasciatus mosquito containing any stage
of W. bancrofti larvae in any body segment and an infec-
tive mosquito was defined as a female C. quinquefasciatus
mosquito containing a 3rd stage W. bancrofti larvae in any
body segment. The remainder of the mosquitoes was used
in PCR assays to detect W. bancrofti DNA as previously
described [6].
Intervention and follow-up
The first mass drug administration (MDA) of diethylcar-
bamazine (DEC) and albendazole took place in October
2000. DEC tablets were offered to all persons older than
two years. Women of childbearing age were excluded
from albendazole treatment at the request of the Ministry
of Health and Population, as described elsewhere [32].
Persons with adverse drug reactions were treated at distri-
bution points, reference centers, or Sainte Croix Hospital,
depending on the severity of the problem.
Cohort data
To monitor the impact of mass treatment on filarial infec-
tion, we investigated a cohort of persons with information
for both the pre- and post-MDA periods. Persons from the
sentinel site who had sufficient volumes of stored sera
from 2000 and 2001 were included in these paired
analyses.
Measurement of filarial specific antibodies
Filarial specific antibodies were measured in sera from the
cohort. The paired sera were assayed for antifilarial immu-
noreactivity (IgG1 and IgG4) with crude Brugia malayi Ag
by enzyme-linked immunosorbent-assay (ELISA) [33,34].
Serum samples were assayed in duplicate at a final dilu-
tion of 1:50 for both IgG assays. Serum samples from non-
traveling North Americans were run in parallel as con-
trols. For both assays, serum samples with antibody levels
greater than or equal to the mean antibody level for non-
traveling North Americans plus 3 standard deviations
(SDs) were considered to be antibody positive. In the con-
tour map analysis, serum samples with antibody levels
greater than the mean antibody level for non-endemic res-
idents of a mountainous area of Haiti plus 3 SDs were
considered to be antibody positive.
Cohort statistical analysis
Univariate differences in proportions (Ag and antibody
prevalence) were analyzed using the Mantel-Haenszel chi-
square or the Fisher exact test. Univariate differences in
continuous measures between groups (antibody level and
average distance to the residence an Ag-positive person)
were compared using pooled t- and Kruksal-Wallis tests.
Univariate analyses on paired data (pre- and post-MDA
values) used Wilcoxon matched-pair signed rank tests for
continuous variables and McNemar's test for binary varia-
bles. All p-values were computed in a manner to account
for sample size.
Household level characteristics
Mapping was used to highlight the spatial distribution of
antifilarial antibody responses and treatment coverage.
Average household responses were calculated by sum-
ming antibody responses of all tested persons in a given
household and then dividing the sum by the total number
of tested household residents. Household antifilarial IgG1
levels were categorized as negative, low positive, and high
positive. Negative antifilarial IgG1 levels were previously
defined. Among households with positive antifilarial
IgG1 responses, the low positive antifilarial IgG1 levels
were defined as those with a mean value less than the
median value of households with at least one positive per-
son; high positive antifilarial IgG1 levels were defined as
those with levels greater than or equal to the median.
Household treatment coverage was defined as the propor-
tion of residents in each household included in the cohort
who reported having taken antifilarial drugs during the
MDA. Three levels of coverage were defined, based on
median household coverage (90%): no coverage, low cov-
erage and high coverage. Households with coverage less
than the median (1–90%) were defined as low coverage,
those with more than the median (91–100%) as high
coverage.
To provide a descriptive representation of the data, a
smoothed contour map was created by summing the anti-
filarial IgG1 levels for residents by household and then
using linear inverse density weighting of the distance to
each household within 50 meters of each point on the
map to create the contours [35]. Quartiles of these
summed (cumulative) levels are represented by shades of
red. Each contour line represents 100 units of change in
antifilarial IgG1 levels. ArcView (v3.3) and the Spatial
Analyst Extension (v2.0) were used to produce antibody
level maps (Environmental Systems Research, Inc., Red-
lands, CA, USA). Clustering was further assessed using
SatSCAN (v. 2.1; National Cancer Institute, Bethesda, MD,Filaria Journal 2004, 3 http://www.filariajournal.com/content/3/1/3
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USA); the number of events in an area was compared to
the number expected based on a Poisson distribution with
a known underlying population at risk [36].
Regression analysis
Multiple linear regression conducted on the cohort was
used to investigate the association of Ag-positive persons
and the antibody responses of other (Ag-negative) mem-
bers of the community. Therefore only people who were
Ag-negative in 2000 were included in the regression anal-
ysis. Ag-positive people were considered potential sources
of transmission, as there were not sufficient micro-
filaremic persons in the community. The outcome varia-
bles were individual antifilarial antibody levels (IgG1 or
IgG4) in 2001. The variable of primary interest was the
distance to the nearest residence of an Ag-positive person
in 2000. The distance was computed from the residence of
Ag-negative people in 2000 to the nearest residence of an
Ag-positive person in 2000 [37,38]. Other variables in the
models included a person's treatment status, age, and gen-
der. Since multiple people from a single household could
be included in our analyses, we used generalized estimat-
ing equation methodology to account for the resulting
within-household correlation [39-41]. We assumed an
exchangeable correlation structure, which assumes a con-
stant correlation between all persons within a given
household. The SAS (v8.2; SAS Institute Inc., Cary, NC,
USA) procedure PROC GENMOD was used for this
modeling.
Results
Mapou sentinel site characteristics
In 2000, the median age of the Mapou population was 18
years, 50.7% of the population was female, and 72.5% of
the residents reported receiving antifilarial drugs in the
first MDA (Table 1). Five hundred eighty-nine residents
were tested in 2000, while 269 were tested in 2001. The
overall prevalence of antigenemia and microfilaremia
decreased after treatment (Table 1). Infection prevalence
in Culex mosquitoes was low at baseline, whether mos-
quitoes were dissected or pooled for PCR [6]. Although
infection prevalence declined following mass treatment,
the decreases we observed were not statistically
significant.
Cohort characteristics
One hundred sixty-one Mapou residents from 80 house-
holds had blood samples collected in both 2000 and
2001. The cohort was similar to the rest of the Mapou sen-
tinel site population with respect to age (median, 18 years
vs. 17 years, p = 0.89) and gender (48.9% vs. 54.0%
female, p = 0.27) distributions.
Of the 161 persons in the cohort, 126 (79%) were treated
in the first MDA (Table 2). Antigenemia prevalence
decreased from 15.0% to 8.7% (p = 0.004) from 2000 to
2001, while microfilaremia prevalence remained constant
at 0.6% (2000, 1/161; 2001, 1/160). In 2000, the preva-
lence of antifilarial IgG1 responses was higher for persons
≤ 20 years of age (68.8%) than for persons > 20 years of
age (44.8%, p = 0.003). Antifilarial IgG4 prevalence was
similar for the two groups (≤ 20 years, 81.7%; > 20 years,
70.1%). Antifilarial antibody prevalence did not change
significantly from 2000 to 2001 for either IgG1 (59.0% to
52.8%) or IgG4 (77.0% to 72.7%, Table 2). Median anti-
filarial antibody levels over this time period remained the
same for both IgG1 (65.9 to 57.1 units) and IgG4 (57.6 to
58.0 units).
Among persons in the cohort who received treatment (N
= 126) antigenemia prevalence decreased significantly
from 2000 to 2001 (14.7% to 5.6%, p = 0.002), antifilar-
ial IgG1 prevalence significantly decreased from 60.3% to
46.0% (p = 0.001), while antifilarial IgG4 prevalence
decreased only slightly (72.2% to 67.5%, p = 0.06, Figure
3). Treated persons had significant declines in median
antifilarial IgG1 responses, from 68.5 to 43.0 units (p =
0.01), while antifilarial IgG4 responses did not change
(57.5 to 55.9 units, p = 0.07, Table 3). Treated persons
who were antibody-positive prior to treatment exhibited a
significant reduction in antifilarial IgG1 levels (p =
Table 1: Characteristics of the entire sentinel site population tested in 2000 and 2001, Mapou, Léogâne Commune, Haiti
2000 2001
Variable N tested N (%) positive Mean SD N tested N (%) positive Mean SD
Gender (female) 578 293 (50.7%) - 0.50 271 140 (51.7%) - 0.50
Age (years) 578 - 24.9 20.17 271 - 26.5 19.64
Antigen + 578 60 (10.4%) - 0.31 269 17 (6.3%) - 0.24
Microfilaremic 587 5 (0.9%) 6.6* 0.09 268 1 (0.4%) 1* 0.06
Drug coverage 269 195 (72.5%) - 0.03 - N/A - N/A
*Microfilaria/ 20 µl among microfilaremic personsFilaria Journal 2004, 3 http://www.filariajournal.com/content/3/1/3
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0.003), but not in antifilarial IgG4 levels (p = 0.06; Figure
4).
Among persons in the cohort who did not receive treat-
ment (N = 34), Ag prevalence did not change from 2000
to 2001 (20.6% to 17.6%, p = 0.57) and antifilarial IgG4
prevalence did not change, (94.1% to 91.2%, p = 0.57),
but antifilarial IgG1 prevalence increased (52.9% to
76.5%, p = 0.003, Figure 3). Median antifilarial antibody
levels did not change for either antifilarial IgG1 (64.5 to
100.0 units, p = 0.10) or antifilarial IgG4 (61.5 to 96.4
units, p = 0.09, Table 3).
Spatial analysis
Sentinel site
Using SaTSCAN software (v2.1), we observed spatial clus-
tering of noncompliance and of infection as determined
by ICT testing. In 2000, untreated persons were clustered
(p = 0.013, cluster radius 0.19 km). This cluster included
68 persons, 33 of whom were untreated. In 2001, there
was significant clustering of Ag-positive persons (p <
0.019; cluster radius 0.67 km), which by visual inspection
tended to occur in an area where drug coverage was low.
Cohort
In 2000, the average distance between the residence of an
Ag-negative person and that of the nearest Ag-positive per-
son was 37.7 meters (median = 20.2 m, range: 0–178.4
m). Average household antifilarial IgG1 levels in 2000
and household treatment coverage varied widely across
Mapou. Similarly, average household antifilarial IgG1
response in 2001 was heterogeneously distributed (Figure
5). Spatial patterns (clusters of households) were evident
for all three measures.
Declines in antifilarial IgG1 levels were observed in
households with the highest treatment coverage, while
antifilarial IgG1 levels remained constant in households
with low coverage (Figure 5). This was most evident in
three clusters with high antifilarial IgG1 levels in 2000
(denoted by the sections 1–3) highlighted in Figure 5. Sec-
tion 1 households had high treatment coverage and corre-
sponding marked decreases in average household
antifilarial IgG1 levels from 2000 to 2001, while sections
2 and 3 had low treatment coverage and stable or
increased average household antifilarial IgG1 levels from
2000 to 2001.
The effect of treatment coverage on total household anti-
filarial IgG1 responses can be seen on a finer scale in Fig-
ure 6, which displays section 3 from Figure 5 in greater
detail, using smoothed contours. A descriptive spatial
smoothing procedure, these contours take into account
the summed antifilarial IgG1 responses from all persons
in all households within a 50-meter radius of each house.
There are two peaks in the top part of section 3 in 2000,
which disappear in 2001, while another peak appears in
the bottom part of section 3. In general, areas with
increased household antifilarial IgG1 responses were
associated with incomplete coverage during the MDA.
Cohort, linear regression
The regression analysis showed that each 10-meter
increase in residential distance from the residence of a per-
son who was Ag-positive in 2000 was associated with a
4.68 unit (5.6%) decrease in antifilarial IgG1 levels in
2001, controlling for treatment status, age, and gender (p
= 0.04, Table 4). Antifilarial IgG1 level decreased follow-
ing treatment, controlling for the other variables (p =
0.03). Being > 20 years of age was associated with a
decrease in antifilarial IgG1 level 2001, controlling for the
other variables (p = 0.01). A separate regression analysis
showed that residential distance from the residence of a
person who was Ag-positive in 2000 was not a significant
predictor of antifilarial IgG4 level in 2001, controlling for
treatment, age, and gender.
Table 2: Characteristics of the Mapou cohort population tested in 2000 and 2001
2000 2001
Variable N tested N (%) positive Mean SD N tested N (%) positive Mean SD p-value
Gender (female) 161 87 (54.0%) - 0.50 - - - - -
Age (years) 160 - 24.7 19.52 - - - - -
Antigen + 160 24 (15.0%) - 0.36 161 14 (8.7%) - 0.28 0.004
Microfilaremic 161 1 (0.6%) 1* 0.08 160 1 (0.6%) 1* 0.08 1.0
Drug coverage 160 126 (78.8%) - 0.41 N/A N/A - N/A -
Antifilarial IgG1 161 94 (58.4%) 122.7 182.5 161 85 52.8% 99.0 146.9 0.11
Antifilarial IgG4 161 125 (77.6%) 104.8 155.4 161 117 72.7% 102.1 215.6 0.052
*Microfilaria/ 20 µl among microfilaremic personsFilaria Journal 2004, 3 http://www.filariajournal.com/content/3/1/3
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Antigen and antifilarial antibody prevalence for A, persons who received treatment (n = 126) and B, persons who did not  receive treatment (n = 34) in 2000 (solid bars) and 2001 (cross-hatched bars) Figure 3
Antigen and antifilarial antibody prevalence for A, persons who received treatment (n = 126) and B, persons who did not 
receive treatment (n = 34) in 2000 (solid bars) and 2001 (cross-hatched bars). The error bar represents the upper 95% 
confidence interval. Among persons who received treatment antigen and antifilarial IgG1 prevalences decreased significantly. 
Among person who did not receive treatment, antifilarial IgG1 prevalence increased significantly.
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Change in antifilarial antibody response among antibody positive persons who received treatment by year Figure 4
Change in antifilarial antibody response among antibody positive persons who received treatment by year. The error bars rep-
resent the non-outlier maximum and minimum values. Outliers were more than 3 standard errors away from the mean. There 
was a significant decrease in antifilarial IgG1 responses (p < 0.001).
Table 3: Median antifilarial IgG levels for the 126 persons in the Mapou cohort who received antifilarial drug treatment in 2000 and the 
34 who did not, by year
Antifilarial Antibody Level*
Treatment status 2000 2001
Received treatment Median (interquartile range) Median (interquartile range) p-value
IgG1 68.5 (22.2–147.5) 43.0 (20.9–85.6) 0.001
IgG4 57.5 (29.9–98.3) 55.9 (21.0–65.9) 0.067
Did not receive 
treatment
IgG1 64.5 (31.9–157.0) 100.0 (52.3–169.7) 0.101
IgG4 61.5 (45.6–104.6) 96.4 (52.40–216.0) 0.088
*units
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Discussion
Overview
In the context of a mass drug distribution, we examined
the spatial relationships before and after treatment
between infection and antifilarial antibody levels in a
community of low W. bancrofti infection prevalence and
limited transmission. We chose an area of low infection
prevalence to represent conditions that are likely to apply
in endemic areas after several rounds of mass treatment.
Such a setting also was chosen to highlight intra-commu-
nity differences, which may not be as obvious in settings
with high W. bancrofti infection. Understanding the rela-
tionship between infection and antibody levels may make
it feasible to use antibody-based assays to define pockets
of ongoing filarial transmission or, in contrast, to be
confident that transmission is absent. A sensitive, specific
antibody-based tool would prove useful to the filariasis
elimination program in both the initial and certification
phases of the effort. Our goal is to develop tools that will
allow us to gauge the impact of the program on transmis-
sion and to conduct surveillance for residual
transmission.
Average antifilarial IgG1 response by household for 2000 (top) and 2001 (bottom), and percent of household members who  received treatment (middle) Figure 5
Average antifilarial IgG1 response by household for 2000 (top) and 2001 (bottom), and percent of household members who 
received treatment (middle). The black line represents the road. Three numbered sections of the community are boxed. Aver-
age antifilarial IgG1 response by household were defined by: the small red circles represent a low level positive response for 
the household; the large red circles represent a high level positive response for the household; and the green circles represent 
a negative response. Household treatment coverage was defined by: the small orange circles represent households with no 
treatment coverage. The small light blue circles represent households with low treatment coverage. The large light blue circles 
represent households with high treatment coverage.
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Smoothed household antifilarial IgG1 response for 2000 (top) and 2001 (bottom) for the third boxed section of the community  as identified in Figure 5 Figure 6
Smoothed household antifilarial IgG1 response for 2000 (top) and 2001 (bottom) for the third boxed section of the community 
as identified in Figure 5. The purple lines represent change in total antifilarial IgG1 response by 100 units. The colored zones 
represent the total household antifilarial IgG1 level in the area of the community. The darker the red area the higher the total 
household antifilarial IgG1 level.
Table 4: Linear Regression: Factors associated with antifilarial IgG1 levels 1 year after mass treatment for 136 persons who were filarial 
antigen negative before treatment (2000), accounting for household clustering in the Mapou cohort
Parameter variables Estimate 95% Confidence Interval p-value
Intercept 181.460 97.500, 265.420 <0.0001
Increase in distance (10 meters) the residence of from an 
Ag-positive person
-4.683 -90.470, -3.180 0.0355
Received treatment -85.387 -164.197, -6.578 0.0337
≤ 20 years of age -45.633 -80.257, -11.008 0.0098
Female gender 21.730 -18.679, 62.140 0.2919
00 . 4
Kilometers 
0.2
0 – 64.19
64.2 – 133.29
133.3 – 316.29
316.3 - 1770
100 unit antifilarial
IgG1 response change
Cumulative household 
antifilarial IgG1 response
N
2000
2001Filaria Journal 2004, 3 http://www.filariajournal.com/content/3/1/3
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Cohort
Antibody response
Antifilarial IgG1 levels, suggested to be a potential marker
of exposure to filarial larvae, have not been extensively
characterized following mass treatment. Among treated
persons, antifilarial IgG1 prevalence and levels declined
significantly after treatment, whereas antifilarial IgG4
level, a potential marker of infection, remained
unchanged, in contrast to previous findings. Wamae and
colleagues (1992) found significant decreases in antifilar-
ial IgG and IgG4 levels 180–720 days after treatment with
DEC; however, their study population consisted only of
microfilaremic individuals [13]. The decrease in
antifilarial IgG1 and the lack of change in antifilarial IgG4
that we observed may be a function of the relatively low
infection loads in Mapou, compared to other studies con-
ducted in the context of drug trials with patients who had
high microfilarial densities.
The regression analysis confirmed that at an individual
level treatment was associated with a significant decrease
in antifilarial IgG1 levels among Ag-negative persons.
These results imply that treatment was associated with
changes in either exposure or infection. Since the
regression analysis excluded Ag-positive persons, it is
likely that the decrease in antifilarial IgG1 level reflects a
reduction in exposure to the parasite (i.e. a decrease in
transmission) rather than a decrease in Ag load. The num-
bers of infected mosquitoes trapped showed little change
in Mapou following treatment, however both the number
of mosquitoes examined and the proportion infected
were relatively small [6].
Importance of spatial relationships
A number of methods were used to analyze and display
the spatial distribution of measures of filarial infection,
exposure to infection, and treatment coverage in Mapou.
Spatial analysis also enabled us to examine the associa-
tion between infected persons, incomplete treatment
coverage, and the distribution of antifilarial antibody
responses throughout the community.
Using linear regression, we estimated the risk an infected
individual posed to his uninfected neighbors. This analy-
sis supported the conclusion that antifilarial IgG1 level
may be a marker of new exposure to filarial larvae (i.e.
marker of ongoing transmission). Increasing distance
between the residences of Ag-negative and Ag-positive
persons was associated with a significant decrease in anti-
filarial IgG1 level, controlling for the other variables.
Every 100-meter increase in distance from the residence of
an Ag-positive person was associated with a 56% decrease
in antifilarial IgG1 level. Increases in antifilarial IgG1
levels may represent continued exposure and therefore,
correspond to inadequate treatment coverage. Regression
analysis indicated that residential distance from the resi-
dence of an Ag-positive individual was not associated with
antifilarial IgG4 level and maps of antifilarial IgG4 levels
showed little change between the two years. These data
argue that antifilarial IgG4 levels are influenced more by
current infection than exposure, as previously suggested
[12,13].
We expected the effect of the mass drug distribution to be
community-wide, but our data provide strong evidence
for micro-scale heterogeneity in the benefits of treatment,
supporting the argument that LF transmission varies at a
micro-scale and low or incomplete treatment coverage in
an area possibly as small as a few households may
influence transmission dynamics (Figures 5 and 6). It is
possible that socioeconomic status might have influenced
coverage levels, although most families in Mapou live in
similar housing without electricity or running water.
Instead, all households may not have been equally recep-
tive to health promotion messages about the drug
distribution. If so, the reasons for this are not clear. In the
future, public health messages should place more empha-
sis on the importance of having one's neighbors receive
treatment with antifilarial drugs.
We had hoped that the entomological data could help us
further define the spatial pattern of LF infection/transmis-
sion in Mapou. However, the small number of infected
mosquitoes collected makes it difficult to comment on
the presence or heterogeneity of transmission in the com-
munity. Practical limitations may prevent us from trap-
ping adequate numbers of mosquitoes to demonstrate
changes in transmission level. The detection of 3rd stage
W. bancrofti larvae in mosquitoes collected in Mapou,
even in small numbers, suggests continued low level
transmission following the 1st MDA. Within a commu-
nity, substantial heterogeneity at the household level in
vector-specific factors (density, biting behavior, etc.)
could exist. The influence of household and individual
factors on LF transmission dynamics has not been fully
described, but may be important in understanding the
spatial heterogeneity of W. bancrofti infection.
Limitations
The cohort (~10–20% of the population) was similar to
the wider Mapou population in terms of demographic
variables and Ag prevalence, although participation was
non-random; factors influencing participation in two
consecutive years may have included health seeking
behaviors, education, and socioeconomic status, some of
which may have been related to infection status. Persons
in the cohort were also slightly more likely to have been
treated during the MDA than non-cohort Mapou resi-
dents. Results also may not be generalizable to other areasFilaria Journal 2004, 3 http://www.filariajournal.com/content/3/1/3
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in Haiti, particularly communities with high infection
prevalences.
Antifilarial IgG1 levels in 2001 were used as the outcome
in the regression analysis. It would have been preferable
to use microfilaremia for these analyses; however, the
number of Mf-positive persons was too small for this pur-
pose (1 positive in each of 2000 and 2001, both persons
with 1 Mf/20 µl).
LF transmission dynamics probably depend on the pres-
ence of microfilaremic people throughout the commu-
nity, not just the nearest person. Operationally, using the
residence of the nearest Ag-positive individual was the
most straightforward. Evaluating the influence of a net-
work of multiple infected persons on antifilarial antibody
status was difficult in a study of this size. We attempted to
address these issues with the contour maps (Figure 6),
which were based on data from all households within a
defined radius, not just a household's nearest neighbor.
Further studies will be necessary to refine this approach.
One potential limitation of assaying antifilarial antibody
responses with crude Brugia malayi Ag is the cross reactiv-
ity with other nematode parasites, including Strongyloides
spp  [4,42,43]. We performed additional analyses to
address this issue and found that intestinal helminth
infection status did not influence antifilarial IgG1
responses in multiple regression or spatial analyses. In the
near future, recombinant Ag assays with greater sensitivity
and specificity for W. bancrofti (and B. malayi) parasite
exposure should be available [43].
Implications for the global program
There is an urgent need for additional tools to help deter-
mine whether mass treatment is necessary in a given area
and when mass treatment can be stopped. The role of the
antibody assay using the crude Brugia malayi Ag in the
monitoring program is at this point undetermined, but it
has provided useful data that have helped to frame
research questions, examine methods, and develop initial
models to assist in measuring exposure. The current anti-
body assays certainly have given us a more detailed view
of transmission in the Mapou community.
Other investigations have noted marked spatial heteroge-
neity of microfilaremia, filarial disease, and antigenemia
in study sites of different sizes [4,10,14,24,44]. Our results
suggest that LF infection is heterogeneous on a much
smaller spatial scale than originally thought and that
transmission dynamics may vary over a distance of
meters.
From our results it is difficult to determine the commu-
nity-wide effect of the MDA. There was little evidence of a
"herd effect" of treatment and the benefits seemed to
occur on a micro-scale level. If these results can be repli-
cated, this could have an influence in determining where
and how treatment programs are implemented and how
certification surveillance is conducted. These data also
emphasize the importance of achieving high and uniform
levels of coverage in order to stop transmission.
The degree to which the spatial heterogeneity of W. ban-
crofti infection and transmission adds to the difficulty of
implementing or evaluating a national treatment strategy
has yet to be fully understood. In a country such as Haiti,
a majority of administrative units fall under the 'transmis-
sion possible but not certain' category; many of these
might be changed to 'transmission present,' if more inten-
sive sampling in the administrative units were done [2].
Based on these uncertainties, any evidence of LF infection
may be enough to warrant MDA, and MDAs may have to
cover much wider areas than anticipated, if goal of
interruption of transmission is to be realized. Finally
micro-scale spatial heterogeneity of infection would make
sampling and certification of areas as transmission-free an
arduous task with the current tools. A consensus on how
to approach and tackle these issues will be vital to the con-
tinued success of the LF elimination program.
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